TP53 mutations characterize high‐grade urothelial carcinoma (HGUC) in the dual pathway of urothelial carcinogenesis, with the mutation rate in HGUC being twofold higher than that in low‐grade tumors.3 Here, TP53 is linked to urothelial carcinoma.